PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
42.50
+2.02 (4.99%)
Oct 29, 2024, 4:00 PM EDT - Market closed
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $186.70M in the quarter ending June 30, 2024, a decrease of -12.68%. This brings the company's revenue in the last twelve months to $900.45M, up 9.98% year-over-year. In the year 2023, PTC Therapeutics had annual revenue of $937.82M with 34.20% growth.
Revenue (ttm)
$900.45M
Revenue Growth
+9.98%
P/S Ratio
3.59
Revenue / Employee
$853,511
Employees
1,055
Market Cap
3.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Envista Holdings | 2.53B |
Amedisys | 2.29B |
Neogen | 912.20M |
Zai Lab | 322.71M |
Rhythm Pharmaceuticals | 101.78M |
Kymera Therapeutics | 88.55M |
Iovance Biotherapeutics | 32.77M |
PTCT News
- 4 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 days ago - PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - PRNewsWire
- 11 days ago - CHMP Maintains Negative Opinion on Translarna™ Reexamination - PRNewsWire
- 15 days ago - PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results - PRNewsWire
- 21 days ago - PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program - PRNewsWire
- 4 weeks ago - PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients - PRNewsWire
- 4 weeks ago - FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program - PRNewsWire
- 6 weeks ago - PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value - Seeking Alpha